PMID- 16176400
OWN - NLM
STAT- MEDLINE
DCOM- 20060406
LR  - 20080528
IS  - 0905-6157 (Print)
IS  - 0905-6157 (Linking)
VI  - 16
IP  - 6
DP  - 2005 Sep
TI  - Three-year follow-up of clinical and inflammation parameters in children 
      monosensitized to mites undergoing sub-lingual immunotherapy.
PG  - 519-26
AB  - Parallel follow-up of clinical and inflammatory markers during sub-lingual 
      immunotherapy (SLIT) is highly beneficial. Twenty-four children (age 4-16) 
      monosensitized to house dust mite were randomized to receive either active or 
      placebo SLIT for 1 yr in a double-blind placebo controlled design (Marcucci et 
      al., Allergy 2003: 58: 657-62). Thereafter, for 2 yr they all received active 
      treatment. Symptom scores for rhinitis, asthma, and drug usage were daily 
      recorded. Eosinophil cationic protein (ECP) and tryptase in sputum and nasal 
      secretions, serum and nasal mite-specific immunoglobulin E (IgE) were recorded 
      before treatment and at 10-12 months intervals. Nasal ECP and nasal tryptase 
      after specific nasal provocation tests were significantly reduced as compared to 
      baseline values (p = 0.0043 and 0.0195, respectively) in the third year of active 
      treatment. None of the other inflammatory parameters was increased. In placebo 
      treated patients all these parameters tended to decrease only after switching to 
      active treatment. Clinical scores did not improve in treated vs. placebo patients 
      in the double-blind placebo-controlled phase of the study. In both cohorts a 
      clinical benefit was observed as intra-group score reduction as compared to 
      baseline. A significant difference was reached in patients treated for 2 yr for 
      rhinitis and asthma (p = 0.0009 and 0.0019, respectively) but not for drug usage 
      and in patients treated for 3 yr for rhinitis, asthma, and drug usage (p = 
      0.0105, 0.0048, and 0.02, respectively). SLIT in children monosensitized to mites 
      reverted the spontaneous increase in nasal IgE and in local parameters of 
      allergic inflammation. These outcomes were followed by a consolidated clinical 
      improvement in the second and third year of treatment.
FAU - Marcucci, F
AU  - Marcucci F
AD  - Clinica Pediatrica, University of Perugia, Italy.
FAU - Sensi, L
AU  - Sensi L
FAU - Di Cara, G
AU  - Di Cara G
FAU - Salvatori, S
AU  - Salvatori S
FAU - Bernini, M
AU  - Bernini M
FAU - Pecora, S
AU  - Pecora S
FAU - Burastero, S E
AU  - Burastero SE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Pediatr Allergy Immunol
JT  - Pediatric allergy and immunology : official publication of the European Society 
      of Pediatric Allergy and Immunology
JID - 9106718
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Inflammation Mediators)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 3.1.27.- (Eosinophil Cationic Protein)
RN  - EC 3.1.27.- (RNASE3 protein, human)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.59 (Tryptases)
SB  - IM
EIN - Pediatr Allergy Immunol. 2006 Jun;17(4):318
CIN - Pediatr Allergy Immunol. 2006 Jun;17(4):315; author reply 316-7. PMID: 16771788
MH  - Administration, Sublingual
MH  - Adolescent
MH  - Animals
MH  - Anti-Asthmatic Agents/*administration & dosage
MH  - Antibody Specificity
MH  - Asthma/drug therapy/*immunology/metabolism
MH  - Child
MH  - Child Welfare
MH  - Child, Preschool
MH  - *Desensitization, Immunologic
MH  - Double-Blind Method
MH  - Eosinophil Cationic Protein/immunology/metabolism
MH  - Follow-Up Studies
MH  - Histamine H1 Antagonists/*administration & dosage
MH  - Humans
MH  - *Immunization
MH  - Immunoglobulin E/blood
MH  - Inflammation Mediators/blood/*immunology
MH  - Pyroglyphidae/drug effects/*immunology
MH  - Rhinitis, Allergic, Perennial/drug therapy/*immunology/metabolism
MH  - Serine Endopeptidases/immunology/metabolism
MH  - Tryptases
EDAT- 2005/09/24 09:00
MHDA- 2006/04/07 09:00
CRDT- 2005/09/24 09:00
PHST- 2005/09/24 09:00 [pubmed]
PHST- 2006/04/07 09:00 [medline]
PHST- 2005/09/24 09:00 [entrez]
AID - PAI301 [pii]
AID - 10.1111/j.1399-3038.2005.00301.x [doi]
PST - ppublish
SO  - Pediatr Allergy Immunol. 2005 Sep;16(6):519-26. doi: 
      10.1111/j.1399-3038.2005.00301.x.